![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
E Richelson and A Nelson
Using radioligand binding techniques, we determined the equilibrium dissociation constants (KDS) for a series of antidepressants at the histamine H1, muscarinic acetylcholine, alpha-1 and alpha-2 adrenergic and dopamine (D-2) receptors of normal human brain tissue obtained at autopsy. Twenty-five different antidepressants were studied at all but the D-2 receptor at which the number was 13 (including a metabolite of an antidepressant). Of all the receptor interactions studied, that at the histamine H1 receptor was in general the most potent interaction of this class of compounds, corresponding to results from studies using animal tissue as the source of receptors. At the human brain histamine H1 receptor, antidepressants remained among the most potent histamine H1 antagonists known, although their affinities for human receptors were lower than those for animal receptors. The most potent and the least potent compounds at the receptors were doxepin (KD = 0.24 nM) and fluvoxamine (KD = 109 microM) at the histamine H1 receptor, amitriptyline (KD = 18 nM) and trazodone (KD = 324 microM) at the muscarinic receptor, doxepin (KD = 24 nM) and viloxazine (KD = 14 microM) at the alpha-1 receptor, mianserin (KD = 73 nM) and bupropion (KD = 81 microM) at the alpha-2 receptor and amoxapine (KD = 160 nM) and trazodone (KD = 3800 nM) at the D-2 receptor, respectively. In general, compared to older drugs, the newer compounds tended to have lower affinities for these receptors.
This article has been cited by other articles:
|
|
 |
|
  D. B. Bylund Selecting selectivities and the neuropharmacology of antidepressant drug action: A commentary FASEB J, November 1, 2007; 21(13): 3417 - 3418. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Bakker, M. W. Nicholas, T. T. Smith, E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 172 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text]
|
|
|
|
 |
|
 Y. Arima, C. Kubo, M. Tsujimoto, H. Ohtani, and Y. Sawada Improvement of Dry Mouth by Replacing Paroxetine with Fluvoxamine Ann. Pharmacother., March 1, 2005; 39(3): 567 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Haddow, D. Harris, M. Wilson, and H. Logie Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin BMJ, December 4, 2004; 329(7478): 1333 - 1335. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Minzenberg, J. H. Poole, C. Benton, and S. Vinogradov Association of Anticholinergic Load With Impairment of Complex Attention and Memory in Schizophrenia Am J Psychiatry, January 1, 2004; 161(1): 116 - 124. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Rijnbeek, S. J. de Visser, K. L. Franson, A. F. Cohen, and J. M. A. van Gerven REM Sleep Effects as a Biomarker for the Effects of Antidepressants in Healthy Volunteers J Psychopharmacol, June 1, 2003; 17(2): 196 - 203. [Abstract] [PDF]
|
|
|
|
 |
|
 Y.-C. Tsai and K.-S. Chu A Comparison of Tramadol, Amitriptyline, and Meperidine for Postepidural Anesthetic Shivering in Parturients Anesth. Analg., November 1, 2001; 93(5): 1288 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Marek, R. A. Wright, D. D. Schoepp, J. A. Monn, and G. K. Aghajanian Physiological Antagonism between 5-Hydroxytryptamine2A and Group II Metabotropic Glutamate Receptors in Prefrontal Cortex J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 76 - 87. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Owens, W. N. Morgan, S. J. Plott, and C. B. Nemeroff Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1305 - 1322. [Abstract] [Full Text]
|
|
|
|
|
|
J. E. Bailey, J. Potokar, N. Coupland, and D. J. Nutt The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man J Psychopharmacol, January 1, 1995; 9(2): 137 - 141. [Abstract] [PDF]
|
|
|
|
|
|
F.S. Guimaraes, A.W. Zuardi, and F.G. Graeff Effect of chlorimipramine and maprotiline on experimental anxiety in humans J Psychopharmacol, January 1, 1987; 1(3): 184 - 192. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
